- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
60 Degrees Pharmaceuticals, Inc. Common Stock(SXTP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SXTP
11/20/2026: SXTP (1-star) is currently NOT-A-BUY. Pass it for now.
60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious and tropical diseases, anchored by its FDA-approved malaria prevention drug, Arakoda. The company's primary growth catalyst lies in advancing its clinical pipeline for novel indications such as severe babesiosis and dengue fever. However, the business faces substantial risks, including very low current revenues, ongoing net losses, capital dilution, and high dependence on clinical trial outcomes. The stock may suit speculative growth investors comfortable with high volatility, while key developments to monitor include upcoming clinical readouts and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high-risk pipeline expansion potential but lacks consistent top-line revenue growth. |
| Momentum investor | Strong fit while signal remains positive | Prone to sharp price movements around clinical data readouts and regulatory updates. |
| Value investor | Weak fit | Unprofitable earnings profile and ongoing cash burn make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company pays no dividends and reinvests all capital into drug development. |
| Low-risk investor | Weak fit | High clinical, regulatory, and financial volatility renders it unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap status and clinical catalyst dependency drive dramatic swings in stock price. |
| Valuation risk | High | Priced heavily on future pipeline optionality rather than current commercial earnings. |
| Competition risk (name the main competitor theme, e.g. AI competition) | Medium / high | Faces intense alternative therapy competition from larger pharmaceutical companies in infectious disease. |
| Business quality | Medium | Has a commercial product and FDA experience, but remains constrained by small scale. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Clinical trial success, regulatory approvals, and capital raising are vital for survival. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.10M USD | Price to earnings Ratio - | 1Y Target Price 3.7 |
Price to earnings Ratio - | 1Y Target Price 3.7 | ||
Volume (30-day avg) 681.6K shares | Beta 2.47 | 52 Weeks Range 0.46 - 5.30 | Updated Date 11/20/2026 |
52 Weeks Range 0.46 - 5.30 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.34 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -65.77% | Avg. Invested days 8 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Pharmaceuticals | Direct sales and distribution of Arakoda for malaria prevention to wholesale and institutional channels. | Generates initial core revenues from one approved specialty drug, though commercial sales remain relatively small. |
| Geography | Primarily the United States market, with select military and international travel health exposure. | Revenue concentration is heavily tied to domestic healthcare and travel markets. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10.94M | Price to Sales(TTM) 2.28 |
Enterprise Value 10.94M | Price to Sales(TTM) 2.28 | ||
Enterprise Value to Revenue 9.85 | Enterprise Value to EBITDA 22.23 | Shares Outstanding 4.48M | Shares Floating 3.12M |
Shares Outstanding 4.48M | Shares Floating 3.12M | ||
Percent Insiders 15.21 | Percent Institutions 19.37 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

